Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you considering substituting infusional 5FU for capecitabine in the FLOT regimen for localized gastric adenocarcinoma?
Answer from: Medical Oncologist at Academic Institution
No. I'm not aware of any high-quality data for such a regimen.
Sign in or Register to read more
3092
Related Questions
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
After R1 resection of a locally advanced, node-positive neuroendocrine tumor of the terminal ilium, would you offer adjuvant radiation therapy?
What systemic therapy would you use in T3N1M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent (chemo>short course RT> resection of primary and liver met)?
How long would you continue trastuzumab for a patient with metastatic HER2+ esophageal adenocarcinoma whose tumor has achieved CR with FOLFOX + trastuzumab and has been disease-free for nearly 3 years?
Would you consider a D2 gastrectomy in young fit patients with gastric adenocarcinoma and positive peritoneal cytology without macroscopic disease if cytology turned negative after neoadjuvant chemotherapy?
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
Do you always biopsy suspicious liver lesions if you have a biopsy from the pancreatic mass showing PDAC?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
How would you approach a case of enteroblastic cholangiocarcinoma?